Evaluation of Antifibrotic Mechanisms of 3′5-Dimaleamylbenzoic Acid on Idiopathic Pulmonary Fibrosis: A Network Pharmacology and Molecular Docking Analysis

Background: Idiopathic pulmonary fibrosis (IPF) is a chronic, disabling disorder of unknown etiology, poor prognosis, and limited therapeutic options. Previously, 3′5-dimaleamylbenzoic acid (3′5-DMBA) was shown to exert resolving effects in IPF, offering a promising alternative for treating this dis...

Full description

Saved in:
Bibliographic Details
Main Authors: Karina González-García, Jovito Cesar Santos-Álvarez, Juan Manuel Velázquez-Enríquez, Cecilia Zertuche-Martínez, Edilburga Reyes-Jiménez, Rafael Baltiérrez-Hoyos, Verónica Rocío Vásquez-Garzón
Format: Article
Language:English
Published: MDPI AG 2024-12-01
Series:Drugs and Drug Candidates
Subjects:
Online Access:https://www.mdpi.com/2813-2998/3/4/48
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850040397141639168
author Karina González-García
Jovito Cesar Santos-Álvarez
Juan Manuel Velázquez-Enríquez
Cecilia Zertuche-Martínez
Edilburga Reyes-Jiménez
Rafael Baltiérrez-Hoyos
Verónica Rocío Vásquez-Garzón
author_facet Karina González-García
Jovito Cesar Santos-Álvarez
Juan Manuel Velázquez-Enríquez
Cecilia Zertuche-Martínez
Edilburga Reyes-Jiménez
Rafael Baltiérrez-Hoyos
Verónica Rocío Vásquez-Garzón
author_sort Karina González-García
collection DOAJ
description Background: Idiopathic pulmonary fibrosis (IPF) is a chronic, disabling disorder of unknown etiology, poor prognosis, and limited therapeutic options. Previously, 3′5-dimaleamylbenzoic acid (3′5-DMBA) was shown to exert resolving effects in IPF, offering a promising alternative for treating this disease; however, the molecular mechanisms associated with this effect have not been explored. Objetive: We evaluated the potential antifibrotic mechanisms of 3′5-DMBA by network pharmacology (NP) and molecular docking (MD). Methods: 3′5-DMBA-associated targets were identified by screening in SwissTargetPrediction. IPF-associated targets were identified using lung tissue meta-analysis and public databases. Common targets were identified, and a protein–protein interaction (PPI) network was constructed; we ranked the proteins in the PPI network by topological analysis. MD validated the binding of 3′5-DMBA to the main therapeutic targets. Results: A total of 57 common targets were identified between 3′5-DMBA and IPF; caspase 8, 9, 3, and 7; myeloid leukemia-induced cell differentiation protein Mcl-1; and poly [ADP-ribose] polymerase 1 are primary targets regulating PPI networks. Functional analysis revealed that the common targets are involved in the pathological features of tissue fibrosis and primarily in the apoptotic process. MD revealed favorable interaction energies among the three main targets regulating PPI networks. Conclusions: NP results suggest that the antifibrotic effect of 3′5-DMBA is due to its regulation of the pathological features of IPF, mainly by modulating signaling pathways leading to apoptosis, suggesting its therapeutic potential to treat this disease.
format Article
id doaj-art-2ea42d65b637499a851982911b3feef7
institution DOAJ
issn 2813-2998
language English
publishDate 2024-12-01
publisher MDPI AG
record_format Article
series Drugs and Drug Candidates
spelling doaj-art-2ea42d65b637499a851982911b3feef72025-08-20T02:56:06ZengMDPI AGDrugs and Drug Candidates2813-29982024-12-013486087810.3390/ddc3040048Evaluation of Antifibrotic Mechanisms of 3′5-Dimaleamylbenzoic Acid on Idiopathic Pulmonary Fibrosis: A Network Pharmacology and Molecular Docking AnalysisKarina González-García0Jovito Cesar Santos-Álvarez1Juan Manuel Velázquez-Enríquez2Cecilia Zertuche-Martínez3Edilburga Reyes-Jiménez4Rafael Baltiérrez-Hoyos5Verónica Rocío Vásquez-Garzón6Laboratory of Fibrosis and Cancer, Faculty of Medicine and Surgery, Autonomous University “Benito Juárez” of Oaxaca, Oaxaca de Juarez 68120, Oaxaca, MexicoLaboratory of Fibrosis and Cancer, Faculty of Medicine and Surgery, Autonomous University “Benito Juárez” of Oaxaca, Oaxaca de Juarez 68120, Oaxaca, MexicoLaboratory of Fibrosis and Cancer, Faculty of Medicine and Surgery, Autonomous University “Benito Juárez” of Oaxaca, Oaxaca de Juarez 68120, Oaxaca, MexicoLaboratory of Fibrosis and Cancer, Faculty of Medicine and Surgery, Autonomous University “Benito Juárez” of Oaxaca, Oaxaca de Juarez 68120, Oaxaca, MexicoLaboratory of Fibrosis and Cancer, Faculty of Medicine and Surgery, Autonomous University “Benito Juárez” of Oaxaca, Oaxaca de Juarez 68120, Oaxaca, MexicoCONAHCYT- Faculty of Medicine and Surgery, Autonomous University “Benito Juárez” of Oaxaca, Oaxaca de Juarez 68120, Oaxaca, MexicoCONAHCYT- Faculty of Medicine and Surgery, Autonomous University “Benito Juárez” of Oaxaca, Oaxaca de Juarez 68120, Oaxaca, MexicoBackground: Idiopathic pulmonary fibrosis (IPF) is a chronic, disabling disorder of unknown etiology, poor prognosis, and limited therapeutic options. Previously, 3′5-dimaleamylbenzoic acid (3′5-DMBA) was shown to exert resolving effects in IPF, offering a promising alternative for treating this disease; however, the molecular mechanisms associated with this effect have not been explored. Objetive: We evaluated the potential antifibrotic mechanisms of 3′5-DMBA by network pharmacology (NP) and molecular docking (MD). Methods: 3′5-DMBA-associated targets were identified by screening in SwissTargetPrediction. IPF-associated targets were identified using lung tissue meta-analysis and public databases. Common targets were identified, and a protein–protein interaction (PPI) network was constructed; we ranked the proteins in the PPI network by topological analysis. MD validated the binding of 3′5-DMBA to the main therapeutic targets. Results: A total of 57 common targets were identified between 3′5-DMBA and IPF; caspase 8, 9, 3, and 7; myeloid leukemia-induced cell differentiation protein Mcl-1; and poly [ADP-ribose] polymerase 1 are primary targets regulating PPI networks. Functional analysis revealed that the common targets are involved in the pathological features of tissue fibrosis and primarily in the apoptotic process. MD revealed favorable interaction energies among the three main targets regulating PPI networks. Conclusions: NP results suggest that the antifibrotic effect of 3′5-DMBA is due to its regulation of the pathological features of IPF, mainly by modulating signaling pathways leading to apoptosis, suggesting its therapeutic potential to treat this disease.https://www.mdpi.com/2813-2998/3/4/48apoptosismaleimidepro-oxidantsPI3K-AktHIF-1αfibroblasts
spellingShingle Karina González-García
Jovito Cesar Santos-Álvarez
Juan Manuel Velázquez-Enríquez
Cecilia Zertuche-Martínez
Edilburga Reyes-Jiménez
Rafael Baltiérrez-Hoyos
Verónica Rocío Vásquez-Garzón
Evaluation of Antifibrotic Mechanisms of 3′5-Dimaleamylbenzoic Acid on Idiopathic Pulmonary Fibrosis: A Network Pharmacology and Molecular Docking Analysis
Drugs and Drug Candidates
apoptosis
maleimide
pro-oxidants
PI3K-Akt
HIF-1α
fibroblasts
title Evaluation of Antifibrotic Mechanisms of 3′5-Dimaleamylbenzoic Acid on Idiopathic Pulmonary Fibrosis: A Network Pharmacology and Molecular Docking Analysis
title_full Evaluation of Antifibrotic Mechanisms of 3′5-Dimaleamylbenzoic Acid on Idiopathic Pulmonary Fibrosis: A Network Pharmacology and Molecular Docking Analysis
title_fullStr Evaluation of Antifibrotic Mechanisms of 3′5-Dimaleamylbenzoic Acid on Idiopathic Pulmonary Fibrosis: A Network Pharmacology and Molecular Docking Analysis
title_full_unstemmed Evaluation of Antifibrotic Mechanisms of 3′5-Dimaleamylbenzoic Acid on Idiopathic Pulmonary Fibrosis: A Network Pharmacology and Molecular Docking Analysis
title_short Evaluation of Antifibrotic Mechanisms of 3′5-Dimaleamylbenzoic Acid on Idiopathic Pulmonary Fibrosis: A Network Pharmacology and Molecular Docking Analysis
title_sort evaluation of antifibrotic mechanisms of 3 5 dimaleamylbenzoic acid on idiopathic pulmonary fibrosis a network pharmacology and molecular docking analysis
topic apoptosis
maleimide
pro-oxidants
PI3K-Akt
HIF-1α
fibroblasts
url https://www.mdpi.com/2813-2998/3/4/48
work_keys_str_mv AT karinagonzalezgarcia evaluationofantifibroticmechanismsof35dimaleamylbenzoicacidonidiopathicpulmonaryfibrosisanetworkpharmacologyandmoleculardockinganalysis
AT jovitocesarsantosalvarez evaluationofantifibroticmechanismsof35dimaleamylbenzoicacidonidiopathicpulmonaryfibrosisanetworkpharmacologyandmoleculardockinganalysis
AT juanmanuelvelazquezenriquez evaluationofantifibroticmechanismsof35dimaleamylbenzoicacidonidiopathicpulmonaryfibrosisanetworkpharmacologyandmoleculardockinganalysis
AT ceciliazertuchemartinez evaluationofantifibroticmechanismsof35dimaleamylbenzoicacidonidiopathicpulmonaryfibrosisanetworkpharmacologyandmoleculardockinganalysis
AT edilburgareyesjimenez evaluationofantifibroticmechanismsof35dimaleamylbenzoicacidonidiopathicpulmonaryfibrosisanetworkpharmacologyandmoleculardockinganalysis
AT rafaelbaltierrezhoyos evaluationofantifibroticmechanismsof35dimaleamylbenzoicacidonidiopathicpulmonaryfibrosisanetworkpharmacologyandmoleculardockinganalysis
AT veronicarociovasquezgarzon evaluationofantifibroticmechanismsof35dimaleamylbenzoicacidonidiopathicpulmonaryfibrosisanetworkpharmacologyandmoleculardockinganalysis